Therapeutic vaccination against human papillomavirus type 16 for the treatment of anal intraepithelial neoplasia in HIV+ men
Phase of Trial: Phase I/II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs ISA 101 (Primary) ; Peginterferon alfa-2a
- Indications Anal cancer; Anal intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms VACCAIN-T
- Sponsors ISA Pharmaceuticals
- 13 Mar 2018 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 05 Aug 2016 Planned End Date changed from 1 Feb 2018 to 1 Jan 2018.